Figure 6. Multimodal neoadjuvant therapy alters the regulatory cell makeup of the tumor microenvironment.

A) Kaplan-Meier survival of patients in this study. There was a trend towards longer survival among patients undergoing neoadjuvant therapy (p = 0.07). B) Quantification of CD11b⁺ (p = 0.04) and CD3⁺cells in neoadjuvant therapy vs. untreated tumors. C) CD4⁺ cells were unchanged, however CD8⁺ cells were less frequent after neoadjuvant therapy (p = 0.04). D) Quantification of FOXP3⁺ cells in treated and untreated tumors (p = 0.002). E) Analysis of ratio of CD8⁺ to FOXP3⁺ T cells (p = 0.01) and CD4⁺ to FOXP3⁺ T cells (p = 0.01) in treated and untreated tumors.